<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548622" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548622/" /><meta name="ncbi_pagename" content="Doxorubicin - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Doxorubicin - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Doxorubicin" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2018/01/15" /><meta name="citation_pmid" content="31643934" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548622/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Doxorubicin" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2018/01/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548622/" /><meta name="description" content="Doxorubicin, epirubicin, idarubicin and valrubicin are structurally related cytotoxic antineoplastic antibiotics used in the therapy of several forms of lymphoma, leukemia, sarcoma and solid organ cancers. Doxorubicin is associated with a high rate of transient serum enzyme during therapy and to rare instances of clinically apparent acute liver injury with jaundice that can be severe and even fatal. Epirubicin and idarubicin have similar profiles of activity and adverse events as doxorubicin, but have been less commonly used and their potential for causing liver injury has been less well defined. Valrubicin is instilled directly in the bladder as treatment of refractory urinary bladder cancer, has little systemic distribution, and has not been associated with serum enzyme elevations or clinically apparent liver injury." /><meta name="og:title" content="Doxorubicin" /><meta name="og:type" content="book" /><meta name="og:description" content="Doxorubicin, epirubicin, idarubicin and valrubicin are structurally related cytotoxic antineoplastic antibiotics used in the therapy of several forms of lymphoma, leukemia, sarcoma and solid organ cancers. Doxorubicin is associated with a high rate of transient serum enzyme during therapy and to rare instances of clinically apparent acute liver injury with jaundice that can be severe and even fatal. Epirubicin and idarubicin have similar profiles of activity and adverse events as doxorubicin, but have been less commonly used and their potential for causing liver injury has been less well defined. Valrubicin is instilled directly in the bladder as treatment of refractory urinary bladder cancer, has little systemic distribution, and has not been associated with serum enzyme elevations or clinically apparent liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548622/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/DoxorubicinEpirubici/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548622/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88F288046597A10000000008E202C4.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548622_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548622_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Doxepin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Doxycycline/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548622_"><span class="title" itemprop="name">Doxorubicin</span></h1><p class="small">Last Update: <span itemprop="dateModified">January 15, 2018</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="DoxorubicinEpirubici.OVERVIEW"><h2 id="_DoxorubicinEpirubici_OVERVIEW_">OVERVIEW</h2><div id="DoxorubicinEpirubici.Introduction"><h3>Introduction</h3><p>Doxorubicin, epirubicin, idarubicin and valrubicin are structurally related cytotoxic antineoplastic antibiotics used in the therapy of several forms of lymphoma, leukemia, sarcoma and solid organ cancers. Doxorubicin is associated with a high rate of transient serum enzyme during therapy and to rare instances of clinically apparent acute liver injury with jaundice that can be severe and even fatal. Epirubicin and idarubicin have similar profiles of activity and adverse events as doxorubicin, but have been less commonly used and their potential for causing liver injury has been less well defined. Valrubicin is instilled directly in the bladder as treatment of refractory urinary bladder cancer, has little systemic distribution, and has not been associated with serum enzyme elevations or clinically apparent liver injury.</p></div><div id="DoxorubicinEpirubici.Background"><h3>Background</h3><p>Doxorubicin (dox&#x0201d; oh roo&#x02019; bi sin), epirubicin (ep&#x0201d; i roo&#x02019; bi sin), idarubicin (eye&#x0201d; da roo&#x02019; bi sin) and valrubicin (val roo' bi sin) are cytotoxic, anthracycline antibiotics which are believed to act by intercalating between DNA base pairs and uncoiling the DNA helix, which results in inhibition of DNA synthesis and the normal DNA breaking and resealing action of DNA toposiomerase II. These actions lead to apoptosis of rapidly dividing cells. These four agents are all semisynthetic derivatives of daunorubicin and share activities and toxicities. All four agents have severe adverse events particularly myelosuppression that can lead to severe neutropenia and sepsis. These agents should be administered only under the supervision of physicians who are experienced in the use of cancer chemotherapeutic agents and in managing their side effects.</p><p>The greatest clinical experience has been with doxorubicin which was previously known as adriamycin. <b>Doxorubicin</b> has potent activity in several forms of cancer, including acute leukemia, lymphomas, sarcomas and solid tumors. Doxorubicin was approved for use in the United States in 1974, and it remains an important agent in many cancer chemotherapeutic regimens. Current indications include treatment of bladder, breast, lung, ovarian stomach and thyroid cancers, Hodgkin disease, acute lymphocytic and non-lymphocytic leukemia, Wilm tumor, neuroblastoma and sarcomas. Doxorubicin is available as a powder for injection and in liquid solution in 10, 20, 50, 100, 150 and 200 mg vials [2 mg/mL] generically and under the brand name Adriamycin. Liposomal formulations are also available. Doxorubicin is typically given intravenously in doses of 60 to 75 mg per meter squared<sup>2</sup> body surface area every 21 to 28 days. The dosage varies by indication, body surface area and hepatic function. Common side effects include bone marrow suppression, nausea, vomiting, mucositis, diarrhea, headache, dizziness, confusion, neuropathy, alopecia, skin rash and fever. High doses or prolonged therapy with doxorubicin can cause serious cardiac toxicity which is a major dose limiting side effect. Local extravasation of doxorubicin causes severe local tissue injury. Long term folllow up studies of treated patients suggest that secondary malignancies may arise more frequently in those who receive high, total accumulative doses of doxorubicin.</p><p><b>Epirubicin</b> is an analogue of doxorubicin that has activity against many forms of cancer, but is used largely in the treatment of advanced breast cancer. Epirubicin was approved for use in the United States in 1999. Current indications are limited to use in patients with breast cancer who have evidence of lymph node involvement after primary resection of the breast tumor. Epirubicin is available as a solution generically and under the brand name Ellence in single use vials containing 50 or 200 mg [2 mg/mL]. The dose of epirubicin is typically 60 to 100 mg per meter squared given in combination with cyclophosphamide and fluorouracil. It is administered by slow intravenous infusion on days 1 and 8 of 28 day cycles. Common side effects are similar to those of doxorubicin and include cardiac toxicity and secondary malignancies.</p><p><b>Idarubicin</b> is an analogue of doxorubicin that has activity against many forms of cancer, but most convincingly in acute myeloid leukemia (AML). Idarubicin was approved for use in the United States in 1990 and is still in common use in various combination chemotherapeutic regimens. Current indications are limited to use in combination with other antineoplastic agents for acute myelogenous leukemia in adults. Idarubicin is available as a solution generically and under the brand name Idamycin in vials and single dose syringes at concentrations of 1 mg/mL. The dose of idarubicin is typically 12 mg per meter squared body surface area, and the dose is adjusted based upon renal and hepatic function. It is administered by slow intravenous infusion daily for 3 days usually in combination with cytarabine, with repeat courses based on tolerance and efficacy. Common side effects are similar to those of doxorubicin and include cardiac toxicity.</p><p><b>Valrubicin</b> is a synthetic analogue of doxorubicin that is used to treat refractory urinary bladder cancer. Valrubicin has been shown to induce clinical remissions in 18% to 30% of pateints. It was approved as a therapy of bladder cancer in the United States 1998, was removed in 2002 because of manufacturing issues, but reintroduced in 2009. Valrubicin is available only for intravesicular use in 5 mL single dose vials of 200 mg under the brand name Valstar. The recommended dose is 800 mg instilled in the bladder once weekly for 6 weeks. Common side effects include bladder pain and irritation, urgency and dysuria. Systemic absorption is minimal and systemic side effects are uncommon.</p></div><div id="DoxorubicinEpirubici.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Serum aminotransferase elevations occur in up to 40% of patients on doxorubicin therapy, but elevations are generally asymptomatic and transient, resolving even with continuation of therapy. However, instances of acute liver injury with symptoms and jaundice have been reported with doxorubicin and rarely also with epirubicin and idarubicin. In most instances, multiple cancer chemotherapeutic agents were being administered and the anthracite antibiotic was believed to enhance the toxicity of the other agents (such as cyclosphosphamide, methotrexate or mercaptopurine). Combination antineoplastic regimens can cause sinusoidal obstruction syndrome, but the role of doxorubicin, epirubicin and idarubicin in this outcome is often not clear. Valrubicin is administered locally in the bladder (intravesical) and has little systemic absorption and has not been linked to serum enzyme elevations during therapy or to clinically apparent liver injury.</p><p>Likehood score (doxorubicin): B (likely cause of clinically apparent liver injury).</p><p>Likehood score (epirubicin and idarubicin): E* (unproven but suspected cause of clinically apparent liver injury).</p><p>Likehood score (valrubicin): E (unlikely cause of clinically apparent liver injury).</p></div><div id="DoxorubicinEpirubici.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>While hepatotoxicity from doxorubicin, epirubicin or idarubicin may be rare, it is likely due to direct toxic injury to the liver. Doxorubicin and its analogues are metabolized in the liver via microsomal enzymes, and production of a toxic or immunogenic intermediate may trigger liver injury.</p></div><div id="DoxorubicinEpirubici.Outcome_and_Managem"><h3>Outcome and Management</h3><p>The severity of the liver injury linked to doxorubicin, epirubicin and idarubicin therapy is usually mild and self-limited. These agents on their own have not been specifically linked to cases of acute liver failure, chronic hepatitis or vanishing bile duct syndrome. There is no information on cross sensitivity to hepatic injury among the various cytotoxic antibiotics, but some degree of cross reactivity should be assumed.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/">Antineoplastic Agents</a></p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/CytotoxicAntibiotics/">Antibiotics, Cytotoxic</a>: <a href="/books/n/livertox/Bleomycin/">Bleomycin</a>, <a href="/books/n/livertox/Dactinomycin/">Dactinomycin</a>, <a href="/books/n/livertox/Daunorubicin/">Daunorubicin</a>, <a href="/books/n/livertox/Mitomycin/">Mitomycin</a>, <a href="/books/n/livertox/Mitoxantrone/">Mitoxantrone</a>, <a href="/books/n/livertox/Plicamycin/">Plicamycin</a></p></div></div><div id="DoxorubicinEpirubici.PRODUCT_INFORMATION"><h2 id="_DoxorubicinEpirubici_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="DoxorubicinEpirubici.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Doxorubicin &#x02013; Generic, Adriamycin&#x000ae;</p><p>Epirubicin &#x02013; Generic, Ellence&#x000ae;, Epimycin&#x000ae;</p><p>Idarubicin &#x02013; Generic, Idamycin&#x000ae;</p><p>Valrubicin &#x02013; Valstar&#x000ae;</p><p><b> DRUG CLASS</b></p><p>Antineoplastic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Doxorubicin" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="DoxorubicinEpirubici.CHEMICAL_FORMULAS_A"><h2 id="_DoxorubicinEpirubici_CHEMICAL_FORMULAS_A_">CHEMICAL FORMULAS AND STRUCTURES</h2><div id="DoxorubicinEpirubici.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548622/table/DoxorubicinEpirubici.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__DoxorubicinEpirubici.T1_lrgtbl__"><table><thead><tr><th id="hd_h_DoxorubicinEpirubici.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_DoxorubicinEpirubici.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_DoxorubicinEpirubici.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_DoxorubicinEpirubici.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Doxorubicin</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">23214-92-8</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C27-H29-N-O11</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548622/bin/Doxorubicin.jpg" alt="Doxorubicin Chemical Structure" /></div></td></tr><tr><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Epirubicin</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">56420-45-2</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C27-H29-N-O11</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548622/bin/Epirubicin.jpg" alt="Epirubicin Chemical Structure" /></div></td></tr><tr><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Idarubicin</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">58957-92-9</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C26-H27-N-O9</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548622/bin/Idarubicin.jpg" alt="Idarubicin Chemical Structure" /></div></td></tr><tr><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Valrubicin</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">56124-62-0</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C34-H36-F3-N-O13</td><td headers="hd_h_DoxorubicinEpirubici.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548622/bin/_56124-62-0.jpg" alt="Image _56124-62-0.jpg" /></div></td></tr></tbody></table></div></div></div><div id="DoxorubicinEpirubici.ANNOTATED_BIBLIOGRA"><h2 id="_DoxorubicinEpirubici_ANNOTATED_BIBLIOGRA_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 15 January 2018</p><ul class="first-line-outdent"><li><div class="bk_ref" id="DoxorubicinEpirubici.R1">Zimmerman HJ. Oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 673-708.<div><i>(Expert review of hepatotoxicity of cancer chemotherapeutic agents published in 1999 mentions that doxorubicin may enhance the hepatotoxicity of other drugs such as mercaptopurine, cyclophosphamide; it has also been implicated in rare instances of acute and chronic hepatitis like disease).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R2">DeLeve LD. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 541-68.<div><i>(Review of hepatotoxicity of cancer chemotherapeutic agents; doxorubicin hepatotoxicity is not discussed).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R3">Chabner BA, Bertino J, Cleary J, Ortiz T, Lane A, Supko JG, Ryan DP. Antibiotics. Cytotoxic agents. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1712-5.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R4">Wang JJ, Cortes E, Sinks LF, Holland JF. Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer 1971; 28: 837-43.  [<a href="/pubmed/4329505" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4329505</span></a>]<div><i>(Among 86 patients with various malignancies who were treated with doxorubicin in various daily regimens and then once weekly, major toxicities were bone marrow suppression, alopecia and gastrointestinal upset; "No significant liver dysfunction was observed as determined by serial serum determinations").</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R5">Tan C, Etcubanas E, Wollner N, Rosen G, Gilladoga A, Showel J, Murphy ML, Krakoff IH. Adriamycin - an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 1973; 32: 9-17.  [<a href="/pubmed/4352019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4352019</span></a>]<div><i>(Among 284 patients with various malignancies treated with doxorubicin in various dose regimens, major toxicities were bone marrow suppression, alopecia, oral ulcers, fever, anorexia and diarrhea and delayed cardiac effects; "no significant change in liver or renal function...was attributed to Adriamycin").</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R6">Rodriguez V, Bodey GP, McCredie KB, Freireich EJ, Minow RA, Casey JH, Luna M. Combination 6-mercaptopurine-adriamycin in refractory adult acute leukemia. Clin Pharmacol Ther 1975; 18: 462-6.  [<a href="/pubmed/1100309" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1100309</span></a>]<div><i>(Among 19 adults with acute leukemia given 5 day courses of mercaptopurine and doxorubicin every 2-3 weeks, 10 developed severe liver toxicity with hepatocellular damage and cholestasis [bilirubin 1.2 to 13.4 mg/dL, AST 115-220 U/L], 2 had ascending cholangitis and one progressive liver failure and death).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R7">Schein PS, Winokur SH. Immunosuppressive and cytotoxic chemotherapy: long-term complications. Ann Intern Med 1975; 82: 84-95.  [<a href="/pubmed/67817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 67817</span></a>]<div><i>(Review of the long term complications of chemotherapy; doxorubicin, like daunorubicin, is associated with cardiac toxicity that is dose limiting; no discussion of doxorubicin hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R8">Minow RA, Stern MH, Casey JH, Rodriguez V, Luna MA. Clinico-pathologic correlation of liver damage in patients treated with 6-mercaptopurine and Adriamycin. Cancer 1976; 38: 1524-8.  [<a href="/pubmed/1068739" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1068739</span></a>]<div><i>(Combination of doxorubicin [50 mg/m<sup>2</sup>/day], mercaptopurine, vincristine and prednisone for acute leukemia was associated with high rate of hepatotoxicity; in 11 cases bilirubin rising with each course with mild elevations in ALT and Alk P; liver tissue showing central cholestasis with mild hepatocellular necrosis and fatty change).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R9">Kun LE, Camitta BM. Hepatopathy following irradiation and adriamycin. Cancer 1978; 42: 81-4.  [<a href="/pubmed/667811" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 667811</span></a>]<div><i>(Two 13 year old children [one boy, one girl] developed severe liver injury after irradiation and doxorubicin therapy for malignancies marked by abdominal pain and ascites [bilirubin 3.8 and 0.8 mg/dL, ALT 137 and 31 U/L, Alk P 17.5 and 5.6 Bodansky U/L], one child dying and one recovering; attributed to hepatic irradiation injury enhanced by doxorubicin).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R10">Hollard D, Sotto JJ, Berthier R, Leger J, Michallet M. High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy: a pilot study. Cancer 1980; 45: 1540-8.  [<a href="/pubmed/6929214" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6929214</span></a>]<div><i>(Among 31 patients with acute leukemia treated with 3 induction regimens [daunorubicin, vincristine, stanazol and prednisone], 7 developed liver injury, but "the liver toxicity seemed to us of little importance", 4 having liver failure which was fatal in one).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R11">Avil&#x000e9;s A, Herrera J, Ramos E, Ambriz R, Aguirre J, Pizzuto J. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med 1984; 108: 912-3.  [<a href="/pubmed/6548368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6548368</span></a>]<div><i>(6 patients with acute leukemia treated with doxorubicin, vincristine and prednisone developed liver test abnormalities during induction [bilirubin 0.8-10.0 mg/dL, ALT 480-1050 U/L, Alk P 150-480 U/L], resolving on stopping therapy and recurring in one patient on restarting doxorubicin).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R12">Schlangen J, Wils J. Liver calcifications following hepatic artery infusion with 5-fluorouracil, adriamycin and mitomycin C (FAM). Rofo 1984; 140: 607-8.  [<a href="/pubmed/6429769" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6429769</span></a>]<div><i>(Among 27 patients with hepatic metastases from colorectal cancer treated with intraarterial infusions of fluorouracil, doxorubicin and mitomycin, one developed extensive liver calcifications shown on liver biopsy to be calcifications within necrotic tumor tissue; the patient was asymptomatic and liver test results were not provided).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R13">Cassileth PA, Begg CB, Bennett JM, Bozdech M, Kahn SB, Weiler C, Glick JH. A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 1984; 63: 843-7.  [<a href="/pubmed/6704545" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6704545</span></a>]<div><i>(Among 283 patients with acute non-lymphocytic leukemia treated with daunorubicin, cytarabine and thioguanine, 77 also received consolidation therapy, 6 [8%] of whom developed severe hepatotoxicity, but no details given).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R14">Sznol M, Ohnuma T, Holland JF. Hepatic toxicity of drugs used for hematologic neoplasia. Semin Liver Dis 1987: 237-56.  [<a href="/pubmed/3317861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3317861</span></a>]<div><i>(Overview of hepatotoxicity of antineoplastic agents, mentions that hepatotoxicity was not detected in single agent trials of doxorubicin and daunorubicin, but evidence implicates them when used in combination with mercaptopurine, cisplatin, cyclophosphamide, and etoposide, possibly due to sinusoidal obstruction syndrome).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R15">Patakfalvi A, Gelencs&#x000e9;r E, S&#x000ed;pos J. Drug hepatitis of cholestatic type in association with a FAC-regimen for breast cancer. Acta Med Hung 1987; 44: 377-85.  [<a href="/pubmed/3444715" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3444715</span></a>]<div><i>(36 year old woman with metastatic breast cancer developed abnormal liver tests after an initial course of chemotherapy that worsened with a second and third course [bilirubin 1.5, 4.8 and 10.5 mg/dL, ALT 600, 4000 and 360 U/L], injury attributed to cyclophosphamide and doxorubicin).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R16">Tanaka H, Kawakami M, Kuraishi Y, Meguro S, Ishikawa E. A comparative pathological study of liver injury after different combination chemotherapies for leukemia. Acta Pathol Jpn 1988; 38: 1417-32.  [<a href="/pubmed/3223277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3223277</span></a>]<div><i>(Description of two different patterns of liver injury associated with cancer chemotherapy).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R17">Pagano L, Sica S, Marra R, Voso MT, Storti S, Di Mario A, Leone G. Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients. Haematologica 1991; 76: 517-8.  [<a href="/pubmed/1820991" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1820991</span></a>]<div><i>(Among 18 elderly patients with leukemia treated with cytarabine and oral idarubicin, 2 developed severe liver injury [bilirubin &#x0003e;20 times ULN] and one died, but few details given).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R18">Hollingshead LM, Faulds D. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 42: 690-719.  [<a href="/pubmed/1723369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1723369</span></a>]<div><i>(Review of the structure, mechanism of action, pharmacology, efficacy and safety of idarubicin; side effects and spectrum of action are similar to doxorubicin).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R19">Soh LT, Ang PT, Sng I, Chua EJ, Ong YW. Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer 1992; 28A: 1338-9.  [<a href="/pubmed/1381211" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1381211</span></a>]<div><i>(4 Chinese patients [ages 29-55 years] with HBsAg developed fatal reactivation of hepatitis B after intensive chemotherapeutic regimens that included doxorubicin).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R20">Coker RJ, James ND, Stewart JS. Hepatic toxicity of liposomal encapsulated doxorubicin. Lancet 1993; 341 (8847): 756.  [<a href="/pubmed/8095649" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8095649</span></a>]<div><i>(Among 27 patients with HIV infection and Kaposi sarcoma treated with liposomal encapsulated doxorubicin, serum enzyme elevations occurred during 14-20% of courses, but were invariably mild [&#x0003c;3 times ULN]).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R21">Avil&#x000e9;s A, Guzm&#x000e1;n R, Talavera A, Garc&#x000ed;a EL, D&#x000ed;az-Maqueo JC. Randomized study for the treatment of adult advanced Hodgkin's disease: epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD). Med Pediatr Oncol 1994; 22: 168-72.  [<a href="/pubmed/7505877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7505877</span></a>]<div><i>(Comparison of different cytotoxic antibiotics combined with bleomycin, vincristine and dacarbazine for Hodgkin disease, found that 6 of 35 given mitoxantrone, but none of 35 treated with epirubicin, developed liver toxicity [AST &#x0003e;3 times ULN], that persisted in 2).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R22">Bertini M, Freilone R, Botto B, Calvi R, Gallamini A, Gatti AM, Liberati AM, et al. Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin). Haematologica 1997; 82: 309-13.  [<a href="/pubmed/9234577" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9234577</span></a>]<div><i>(Comparison of VACOP vs VICOP induction therapy in 104 patients with lymphoma, found hepatotoxicity occurred in 4% on doxorubicin vs 12% on idarubicin).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R23">Faggioli P, De Paschale M, Tocci A, Luoni M, Fava S, De Paoli A, Tosi A, Cassi E. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica 1997; 82: 38-42.  [<a href="/pubmed/9107080" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9107080</span></a>]<div><i>(Among 98 patients with non-Hodgkin lymphoma treated with various chemotherapeutic regimens [21 of which included doxorubicin in ProMACE-CytaBOM], 20 had transient ALT elevations and 12 acute hepatitis, 8 of whom were HBsAg positive and frequently had evidence of reactivation).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R24">Greenberg RE, Bahnson RR, Wood D, Childs SJ, Bellingham C, Edson M, Bamberger MH, et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 1997; 49: 471-5.  [<a href="/pubmed/9123721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9123721</span></a>]<div><i>(Among 32 patients with superficial transitional cell carcinoma of the bladder who were treated with 6 weekly doses of valrubicin instilled directly in the bladder, 13 [42%] had a complete clinical response, side effects were due mainly local irritation in the bladder and there were no changes in routine laboratory tests).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R25">Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, Franklin J, et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol 1999; 78: 418-25.  [<a href="/pubmed/10525830" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10525830</span></a>]<div><i>(Trial of idarubicin with 3 other agents in patients with refractory, relapsed or secondary AML identified major toxicities of bone marrow suppression, infections, nausea, diarrhea, fever and bleeding, but serious hepatic toxicity was "rarely observed").</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R26">Valrubicin for bladder cancer. Med Lett Drugs Ther 1999; 41 (1049): 32.  [<a href="/pubmed/10232952" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10232952</span></a>]<div><i>(Concise review of the mechanism of action, clinical efficacy, safety and costs of valrubicin shortly after it was approved for use in the US as treatment of bladder cancer; no mention of liver injury or serum enzyme elevations).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R27">Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000; 163: 761-7.  [<a href="/pubmed/10687972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10687972</span></a>]<div><i>(Among 90 patients with recurrent, refractory in situ bladder cancer who received 6 weekly intravesical instillations of valrubicin, 19 [21%] had a complete response and adverse events inlcuded bladder irritation, frequency and dysuria).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R28">Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, et al.; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100: 3141-6.  [<a href="/pubmed/12384411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12384411</span></a>]<div><i>(Comparison of induction therapy with idarubicin alone versus idarubicin and cytarabine in 257 patients with acute leukemia, found hepatotoxicity in 7.6% on idarubicin alone [1 death from liver failure] versus 7.1% on the combination, but few details given).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R29">Ma B, Yeo W, Hui P, Ho WM, Johnson PJ. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer - a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 2002; 62: 185-9.  [<a href="/pubmed/11937245" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11937245</span></a>]<div><i>(Among 85 women with breast cancer treated with doxorubicin and cyclophosphamide, severe hepatotoxicity occurred only in HBsAg positive patients).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R30">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i> (Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, several cases were attributed to antineoplastic agents [such as mercaptopurine, cyclophosphamide, docetaxel, temozolomide, bortezomib and imatinib], but none to the cytotoxic antibiotics such as doxorubicin or daunorubicin).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R31">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, including 2 attributed to antineoplastic agents, 1 to melphalan and 1 to gemtuzumab, but none to a cytotoxic antibiotic such as bleomycin, doxorubicin or daunorubicin).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R32">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Ann Hepatol 2014; 13: 231-9. (Among 176 reports of drug induced liver injury from Latin American published between 1996 and 2012, 10 were attributed to antineoplastic agents including methotrexate, imatinib, cyclophosphamide, procarbazine and tamoxifen, but none were attributed to doxorubicin or other cytotoxic antibiotics). [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]</div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R33">Damodar G, Smitha T, Gopinath S, Vijayakumar S, Rao Y. An evaluation of hepatotoxicity in breast cancer patients receiving injection Doxorubicin. Ann Med Health Sci Res 2014; 4: 74-9.  [<a href="/pmc/articles/PMC3952301/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3952301</span></a>] [<a href="/pubmed/24669335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24669335</span></a>]<div><i> (Among 46 patients with breast cancer treated with doxorubicin, 30% developed ALT, AST or bilirubin elevations, but the duration and severity of the abnormalities was not provided).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R34">Cookson MS, Chang SS, Lihou C, Li T, Harper SQ, Lang Z, Tutrone RF. Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder. Ther Adv Urol 2014; 6: 181-91.  [<a href="/pmc/articles/PMC4144261/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4144261</span></a>] [<a href="/pubmed/25276228" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25276228</span></a>]<div><i>(Among 113 patients with superficial bladder cancer treated with intravesical instillation of valrubicin, local advrse events occurred in 50% and were usually mild; no mention of systemic effects and none of the 7 listed serious adverse events were liver related).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R35">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 49 were attributed to antineoplastic agents, but none to doxorubicin, epirubicin or idarubicin).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R36">Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, et al. Summary and recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer 2016; 2: 165-202.  [<a href="/pmc/articles/PMC4927845/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4927845</span></a>] [<a href="/pubmed/27376138" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27376138</span></a>]<div><i>(Research workshop on needs for innovative therapies for bladder cancer, there having been no new FDA approved drugs since the introduction of valrubicin in 1998). </i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R37">Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 2016; 388 (10043): 488-97.  [<a href="/pmc/articles/PMC5647653/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5647653</span></a>] [<a href="/pubmed/27291997" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27291997</span></a>]<div><i>(Among 133 patients with soft tissue sarcoma treated with doxorubicin with or without olaratumab for up to 8 cycles of 21 days, overall and progression free survival improved with addition of olaratumab, but adverse event rates were also higher, although there were no elevations in serum ALT or AST levels above 5 times ULN in either group).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R38">Janni W, Harbeck N, Rack B, Augustin D, Jueckstock J, Wischnik A, Annecke K, et al. Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. Br J Cancer 2016; 114: 863-71.  [<a href="/pmc/articles/PMC4984804/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4984804</span></a>] [<a href="/pubmed/27031854" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27031854</span></a>]<div><i>(Among 1493 women with metastatic breast cancer treated with epirubicin and cyclophosphamide with either fluorouracil or docetaxel, there were no differences in overall survival between the treatment arms, but serious adverse events were higher with fluorouracil [30% vs 23%] while ALT elevations above 5 times ULN occurred at similar low rates [ 0.9% vs 1.5%]).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R39">Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 2016; 34: 2046-53.  [<a href="/pmc/articles/PMC4966514/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4966514</span></a>] [<a href="/pubmed/26834067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26834067</span></a>]<div><i> (Among 101 patients with hepatocellular carcinoma treated with transarterial embolization using microspheres with or without doxorubicin-loading, there were no differences in overall or progression free survival or in adverse event rates; ALT elevations were not specifically mentioned).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R40">Nam HC, Jang B, Song MJ. Transarterial chemoembolization with drug-elutingbeads in hepatocellular carcinoma. World J Gastroenterol 2016; 22: 8853-61.  [<a href="/pmc/articles/PMC5083790/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5083790</span></a>] [<a href="/pubmed/27833376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27833376</span></a>]<div><i> (Review of the safety and efficacy of doxorubicin eluting beads for use in TACE treatment of hepatocellular carcinoma discusses the advantage of this treatment approach because of lack or minimal systemic exposure to doxorubicin).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R41">Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017; 18 (10): 1397-1410.  [<a href="/pmc/articles/PMC5622179/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5622179</span></a>] [<a href="/pubmed/28882536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28882536</span></a>]<div><i>(Among 257 patients with advanced metastatic soft tissue sarcoma treated with 6 cycles of doxorubicin vs gemcitabine with docetaxil, progression free survival was the same with both treatments and adverse event rates were comparable; ALT elevations occurring in 27% vs 29% which were above 5 times ULN in 1% vs 1%).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R42">Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2017; 18: 1089-103.  [<a href="/pmc/articles/PMC7771354/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7771354</span></a>] [<a href="/pubmed/28651927" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28651927</span></a>]<div><i>(Among 640 patients with advanced soft tissue sarcoma treated with doxorubicin with or without evofosfamide, overall survival was the same in both groups, while side effects were less with monotherapy including ALT elevations [1% vs 3.5%], none of which were above 5 times ULN).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R43">Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, et al.; tAnGo trial collaborators. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18: 755-69.  [<a href="/pubmed/28479233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28479233</span></a>]<div><i>(Among 3152 women with early stage breast cancer treated with epirubicin, paclitaxel and cyclophosphamide with or without gemcitabine, disease free survival did not differ between the two treatment arms, while adverse events were more frequent with the addition of gemcitabine; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R44">Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, et al. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Ann Oncol 2017; 28: 996-1004.  [<a href="/pmc/articles/PMC5406764/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5406764</span></a>] [<a href="/pubmed/28453702" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28453702</span></a>]<div><i>(Among 297 women with advanced ovarian cancer treated with pegylated liposomal doxorubicin with or without motolimod [a toll-like receptor 8 agonist], overall survival and adverse event rates were similar in the 2 treatment arms; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="DoxorubicinEpirubici.R45">Harbeck N, Saupe S, J&#x000e4;ger E, Schmidt M, Kreienberg R, M&#x000fc;ller L, Otremba BJ, et al.; PELICAN Investigators. A randomized phase III study evaluating pegylated liposomaldoxorubicin versus capecitabine as first-line therapy for metastatic breastcancer: results of the PELICAN study. Breast Cancer Res Treat 2017; 161: 63-72.  [<a href="/pmc/articles/PMC5222915/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5222915</span></a>] [<a href="/pubmed/27798749" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27798749</span></a>]<div><i>(Among 210 women with metastatic breast cancer treated with pegylated liposomal doxorubicin every 28 days or capecitabine, there were no differences in time to progression between the two treatment arms while adverse events were more common with capecitabine; no mention of ALT elevations or hepatotoxicity).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548622</span><span class="label">PMID: <a href="/pubmed/31643934" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643934</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Doxepin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Doxycycline/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548622&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548622/?report=reader">PubReader</a></li><li><a href="/books/NBK548622/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548622" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548622" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Doxorubicin. [Updated 2018 Jan 15].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548622/pdf/Bookshelf_NBK548622.pdf">PDF version of this page</a> (434K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Doxorubicin+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Doxorubicin: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Doxorubicin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Doxorubicin: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4858884" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4858884" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/10459733" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Valrubicin.</a><span class="source">[Drugs Aging. 1999]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Valrubicin.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Onrust SV, Lamb HM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs Aging. 1999 Jul; 15(1):69-75; discussion 76. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/2944917" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.</a><span class="source">[J Clin Pharmacol. 1986]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wadler S, Fuks JZ, Wiernik PH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Pharmacol. 1986 Sep-Oct; 26(7):491-509. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/9129933" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells.</a><span class="source">[Eur Urol. 1997]</span><div class="brieflinkpop offscreen_noflow">Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Siegsmund MJ, Stendler A, Kreukler C, Khrmann KU, Alken P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur Urol. 1997; 31(3):365-70. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643438" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Bendamustine</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Bendamustine<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/1586980" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.</a><span class="source">[Cancer Chemother Pharmacol. 1992]</span><div class="brieflinkpop offscreen_noflow">Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kuffel MJ, Reid JM, Ames MM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cancer Chemother Pharmacol. 1992; 30(1):51-7. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643934" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643934" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604680090831bd466645099c">Doxorubicin - LiverTox</a><div class="ralinkpop offscreen_noflow">Doxorubicin - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:50:34-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal101&amp;ncbi_phid=CE88F288046597A10000000008E202C4&amp;ncbi_session=CE88F28804680081_2274SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548622%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548622&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548622/&amp;ncbi_pagename=Doxorubicin - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88F28804680081_2274SID /projects/books/PBooks@9.2 portal101 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>